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The complement system consists of effector proteins, regulators, and receptors that participate in host defense against pathogens. Activation of the complement system, via the
classical pathway (CP), has long been recognized in immune complex-mediated tissue
injury, most notably systemic lupus erythematosus (SLE). Paradoxically, a complete deficiency of an early component of the CP, as evidenced by homozygous genetic deficiencies
reported in human, are strongly associated with the risk of developing SLE or a lupus-like
disease. Similarly, isotype deficiency attributable to a gene copy-number (GCN) variation
and/or the presence of autoantibodies directed against a CP component or a regulatory
protein that result in an acquired deficiency are relatively common in SLE patients. Applying
accurate assay methodologies with rigorous data validations, low GCNs of total C4, and
heterozygous and homozygous deficiencies of C4A have been shown as medium to large
effect size risk factors, while high copy numbers of total C4 or C4A as prevalent protective
factors, of European and East-Asian SLE. Here, we summarize the current knowledge
related to genetic deficiency and insufficiency, and acquired protein deficiencies for C1q,
C1r, C1s, C4A/C4B, and C2 in disease pathogenesis and prognosis of SLE, and, briefly, for
other systemic autoimmune diseases. As the complement system is increasingly found to
be associated with autoimmune diseases and immune-mediated diseases, it has become
an attractive therapeutic target. We highlight the recent developments and offer a balanced
perspective concerning future investigations and therapeutic applications with a focus on
early components of the CP in human systemic autoimmune diseases.
Keywords: systemic lupus erythematosus, complement C1q, complement C4, autoimmune diseases, complement
C2, complement C1s, complement C1r, classical pathway

ACTIVATION OF THE COMPLEMENT SYSTEM
The complement system is a humoral recognition and effector system that facilitates in the elimination
of invading pathogens. The activation pathways of the complement system converge at C3 and progress to the formation of the membrane attack complexes (MAC or C5b–C9) on a target membrane.
The cascades of complement system are mediated and adjusted according to the type of initiator
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and the microenvironment in which complement activation is
occurring. Proteins of the complement system cooperate and
coordinate to differentiate among invading microbes, immune
complexes, apoptotic cells, cellular debris, and physiologic host
cells (1–4).
Three distinct pathways trigger cascades of activation through
proteolysis of zymogens or precursors present in the circulation
(Figure 1). The classical pathway (CP) is predominantly triggered
by IgM or IgG immune complexes. The formation of antigen–
antibody complexes exposes binding sites for C1q on Fc-regions
of immunoglobulins, triggering the assembly and activation of
the multi-molecular C1 complex, C1q–C1r2–C1s2 (pathway
3, Figure 1). Conformational changes in the C1 complex are
induced upon binding of C1q to antibody, leading to activation
of the serine protease subunits C1r and then C1s. As a result, C1s
next activates C4 and C2, leading to the formation of the CP C3
convertase (abbreviated C4b2a). Following the early components
activation, later components of the complement cascade form
the MAC, which perturbs membranes, including the creation
of pores across the target membrane, inducing cell lysis, loss of
cytoplasm, and osmotic shock.
In the mid-1950s, Pillemer and colleagues of Case Western
Reserve University observed that complement activation could
occur in the absence of a specific antibody (5). The existence of
such an “alternative” pathway (AP) of activation was challenged
but was confirmed more than two decades later (6). Specific
protein factors involved in this AP are named factors, such as
factor B, factor D, factor H (FH), and factor P (properdin). This

pathway is initiated by a “tick-over” mechanism, in which a small
proportion of complement C3 in the circulation is continuously
hydrolyzed at slow rate (~1–2%/h) by water to form C3(H2O).
C3(H2O) binds to factor B, which is activated by factor D, to form
C3(H2O)Bb. C3(H2O)Bb accordingly acts as a relatively labile C3
convertase, constantly initiating C3 cleavage. Properdin stabilizes
the short-lived C3 convertase. Under the appropriate circumstances, a C5 convertase (C3bBbP) is formed, and the cascade
progresses to MAC formation on a foreign cell surface, similar to
that of the CP (pathway 1, Figure 1). The binding of P to C3bBb
on a microbial (or protected) surface will stabilize and protect
the convertase from inactivation by regulatory proteins, thereby
enhancing the convertase activity. The AP actually represents an
ancient mechanism of innate immune host defense. The tickover mechanism of complement activation enables a continuous
surveillance for the host, executing the first line of defense against
foreign invaders. With the development of a circulatory system,
a system of host defense that both worked in seconds and was
pathogen-destructing became mandatory.
A third pathway of complement activation involves the
specific pattern recognition of biomolecules. One strategy for
organisms to achieve species-specific diversity is by modification
of biomolecules such as glycolipids and glycoproteins with different complexities of sugars. Typically, carbohydrate moieties on
glycoproteins among vertebrates consist of complex sugars with
secondary modifications (biantennary type) and ending with
sialic acids. By contrast, the carbohydrate moieties in prokaryotes generally consist of simpler polymers of saccharides such

FIGURE 1 | The activation pathways of the complement system. The three activation pathways of the complement system are shown according to evolution
and physiologic sequences. Pathway 1 is known as the alternative pathway. It is activated through a tick-over mechanism because of continuous hydrolysis of the
thioester bond in C3, which enables the formation with factor B to form a weak C3 convertase. Pathway 2 is known as the MBL or lectin pathway. It is initiated
through the binding of mannan-binding lectin (MBL) or ficolin to arrays of simple sugar molecules in glycosylated antigens on microbes. This is a pattern recognition
mechanism characteristic of the innate immune system. Pathway 3 is known as the classical pathway and is initiated through the binding of specific antibodies IgM
or IgG to antigens. It is an effector arm of the humoral adaptive immune system. Each activation pathway engages the formation of a multi-molecular initiation
complex, followed by the assembly of a C3 convertase and a C5 convertase for activation of C3 and C5, respectively and culminates in the formation of membrane
attack complexes (MAC) on the target membrane. All three pathways can be amplified through a positive feedback mechanism, as C3b (in blue) generated by any
C3 convertase can feed to the alternative pathway through association with factor B to form new C3 convertase after activation by factor D (pathway 1).
Anaphylatoxins C3a and C5a are produced during the activation process. For brevity, by-products generated during the activation of C2 and factor B are not shown.
Red arrows show activation of component proteins through cleavage by serine proteases. A dotted horizontal arrow denotes multiple steps are involved in the
formation of the membrane attack complex. Early components of the classical pathway C1q, C1r, C1s, and C4 are engaged in the differentiation of immunity and
autoimmunity, as genetic or acquired deficiency in any of these components are linked to pathogenesis of SLE. Complement C2 is also involved in the protection
against autoimmunity but its effect size is smaller [modified from Ref. (2)].

Frontiers in Immunology | www.frontiersin.org

2

February 2016 | Volume 7 | Article 36

Lintner et al.

Early Complement in Human Systemic Autoimmune Diseases

as mannose. Pattern recognition of biomolecules is a universal
theme of innate immunity. This pathway of complement activation is initiated by the binding of pattern recognition molecules
including mannan-binding lectin (MBL) or ficolins to a bacterial
membrane that express arrays of simple carbohydrates such as
mannose and N-acetylglucosamine (7, 8). Such binding triggers
the assembly of MBL/MASP2 and ficolin/MASP2 or MBL/MASP1
and ficolin/MASP1 complexes (pathway 2, Figure 1). MASP2 and
MASP1 are both serine proteases. MASP2, associated with MBL
or ficolin, activates both C4 and C2. As a result, a C3 convertase
identical to that generated by the CP is formed.
Thus, all three complement activation pathways pass through
the focal point on the activation of C3 to C3a and C3b, and then
C5a and C5b, leading to the assembly of sublytic or lytic complexes
on target membrane. It is noteworthy that all three activation
pathways can be amplified by the positive feedback mechanism
of the AP. In addition to cell lysis, effects of complement activation include opsonization to enhance phagocytosis of target
cells, clearance of apoptotic bodies, solubilization and removal
of immune complexes, stimulation of cytokine production, and
anaphylatoxin-mediated effects. To summarize, the complement
system has been designed in evolution primarily to activate on the
membranes of bacteria and certain viruses. Opsonization via C3b
and cellular activation via the anaphylatoxins C3a and C5a are its
two primary functions.

surfaces, allows the regulators to prevent activation on host tissues
while restricting complement activity to designated, foreign targets. Dysfunctional or uncontrolled complement activation can
lead to destruction of body cells, overt release of inflammatory
mediators, and tissue damage, as evidenced by clinical complications experienced by systemic lupus erythematosus (SLE) patients.

COMPLEMENT IN SYSTEMIC LUPUS
ERYTHEMATOSUS
Serum C4 and C3 Levels

Systemic lupus erythematosus patients commonly present with
evidence of complement consumption leading to low serum
levels of C4 and C3 (9, 10). Initially, up to one-half of SLE patients
will have low C4 and C3. In most established patients, serum C4
levels are biomarkers for lupus disease activity; low levels correlate
with a flare, while normal levels correspond with remission (11).
Longitudinal studies of serum C4 protein levels in SLE patients
revealed different expression profiles characterized by three distinct groups (Figure 2) (12). The first group exhibited persistently
low C4 levels throughout the course of the study, and many of
these patients had a low copy number of C4 genes. The second
group featured periodic fluctuations of C4 that paralleled disease
activity while the third group had normal C4 levels most of the
time. The typical pattern in active SLE patients is that both C4
and C3 are low simultaneously. However, exceptions occur. C3
levels are usually three- to sixfold higher than C4 levels; therefore,
consumption of complement by immune complexes could reduce
C4 below normal but leave C3 in the normal range. With a positive
response to treatment, both C4 and C3 levels will rise. As noted,
up to one-half of SLE patients will present with serum C4 and C3
in a normal range, which obviously does not rule out a lupus diagnosis. The CH50 and AP50 measure the lysis of red blood cells by
the respective pathway and thus are functional tests. Furthermore,
in vivo complement activation can also be assayed by testing for
complexes or split products formed during activation (3).
Copy-number variation (CNV) of C4 can affect serum C4
protein concentrations. In an American Caucasian populations,
about 60% of individuals have four copies of the C4 gene, 28.5%
have three (or less), and 12.5% have five (or more). In lupus, the
number of patients with three or less C4 genes may increase to
42.2% (13). If an individual has low copy of C4 genes, the baseline
C4 antigenic level may be 12–18 (~6 to 8 mg/dL per copy of a C4
gene). In this situation, it does not take much activation to lower
the C4 out of the normal range. Additionally, a subject’s body
mass index (BMI) is positively associated with serum C4 or C3
protein concentrations (14, 15). All things considered, the care
of each patient must be individualized. Repeated, longitudinal
serum measurements of C3 and C4 are usually clinically utilized.

REGULATION OF THE COMPLEMENT
SYSTEM
Because the activated complement components C4b, C3b, and
C5b67 can attach to any nearby cell surfaces including host cells,
regulatory mechanisms have evolved to contain complement activation to damaged self and foreign targets. Inherently, all activated
complement proteins spontaneously undergo intrinsic decay or
inactivation when not stabilized by other pathway components
or factors. In addition, several regulatory proteins in plasma or
on the cell membrane can dissociate (decay) multi-molecular
(activated) complexes and also proteolytically degrade the anchor
proteins such as C4b and C3b. Upon initiation of classical or lectin
pathways, C1-inhibitor (C1-INH) is a serine protease inhibitor
that mimics the substrates for C1s in the C1 complex, and MASP2
or MASP1 in the MBL or ficolin complex. C1-INH forms a complex with activated C1r and C1s leading to the dissociation of the
enzymatic C1r/C1s subunit from the recognition C1q subunit
and preventing further activation of C4 and C2.
Importantly, there are also key strategies of regulation that act
upon the assembly and stability of the C3 convertases. Fluid phase
proteins, C4b-binding protein (C4bp) and FH and membrane
proteins complement receptor 1 (CR1) and decay accelerating factor (DAF) all dissociate the recognition and enzymatic subunits
of C3 convertases. Moreover, C4bp, CR1, and membrane cofactor
protein (MCP) serve as cofactor proteins for factor I-mediated
degradation of C4b, while FH, CR1, and MCP each serves as a
cofactor for the factor I-mediated proteolysis of C3b. Notably,
C4bp and FH recognize exposed host glycoproteins with glycosaminoglycans and sialic acids. The presence of such regulatory
molecules on self-surfaces, but absence from most foreign particle
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activation products (CBCAPS), especially erythrocyte-bound
C4 (E-C4d), has been proposed to assist in the diagnosis and
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clinical monitoring of SLE (16, 17). E-C4d is a stable, proteolytic
end fragment of C4, which is covalently bound to the surface of
erythrocytes following activation of the CP or MBL pathway. On
cell surfaces, the activated C4b is processed to the cell-bound
C4d with the release of soluble C4c through factor-I mediated
proteolysis in the presence of a cofactor (i.e., CR1 or MCP on the
plasma membrane or C4bp from plasma). In 2004, Manzi et al.
found that erythrocytes from SLE patients had markedly higher
levels of E-C4d when compared to healthy controls or patients
with other diseases (16). Additional studies explored the utility
of CBCAPS on T and B lymphocytes, platelets, and reticulocytes
in SLE (18–21). The levels of C4d bound to the membrane of
these cells were significantly higher in SLE than healthy controls
or patients with other diseases. In a study of 304 SLE patients, 285
patients with other rheumatic diseases and 205 healthy controls,
Putterman and colleagues reported that CBCAPS on erythrocytes
or B cells had higher sensitivity than standard complement levels
(serum C3 and C4) and anti-dsDNA measurements when distinguishing between SLE and non-SLE, suggesting that CBCAPS
could be more specific and sensitive biomarkers for diagnosis and
prognosis of SLE (17). However, given the relative simplicity and
low cost of serum C4 and C3 measurements, it remains to be seen
how assessment of cell-bound C4d and C3d will contribute to the
clinical care of patients with SLE.
Historically, cell-bound complement activation proteins,
particularly those of C4d, have offered clues to several important
discoveries. Between 1960 and 1990, it was found that blood group
antigens, Chido (Ch) and Rodgers (Rg), were polymorphic variants of complement C4 (22–24). Alloantibodies generated against
Ch/Rg antigens after blood transfusion in certain recipients were
mostly directed against polymorphic amino acids present in the
C4d region of C4B and C4A proteins, respectively. The mapping
of the Ch/Rg variants to the HLA contributed to the understanding of MHC genetics. The polymorphisms of C4A and C4B
protein allotypes are readily demonstrated by immunofixation
of EDTA-plasma resolved by high voltage, agarose gel electrophoresis based on gross differences of electric charge of protein
molecules resulting in variations in electrophoretic mobilities
(25–27). Using an assay that involved an overlay of “sensitized”
sheep red blood cells on the described C4-allotyping gels, it was
found that C4B proteins are functionally 4–10 times more active
on the hemolysis of sheep red blood cells (26, 28, 29). While most
C4A are associated with Rg antigens and C4B with Ch antigens,
reverse associations such as C4A1 with Ch and C4B5 with Rg were
demonstrated (23, 30). It was the cloning and sequencing of those
functional and serological variants that enabled the identification
of specific isotype residues at positions 1120–1125, PCPVLD for
C4A and LSPVIH for C4B, encoded by exon 26 of the C4 gene
(31, 32). The major epitopes for Rg and Ch blood groups were
mapped to positions 1207–1210, VDLL for Rg and ADLR for Ch,
encoded by exon 28 of C4 genes (32). Detailed characterization
of C4A and C4B genetic polymorphisms unraveled a surprising
phenomenon: CNVs and gene size dichotomy among human
subjects with specific distribution patterns among different racial
populations (13–15, 33, 34).

FIGURE 2 | Typical serial serum protein profiles of complement C4
and C3 in human SLE patients. Serum C4 (red, solid line) and C3
(green, dashed line) protein levels tend to go up and down together in
most SLE patients. The horizontal dotted line indicates the low level of
serum C4 (<10 mg/dL), below which usually requires clinical attention.
The profiles shown are taken from three individual patients over a
24-month period and represent three common profiles typically observed
in SLE patients. In the first profile (A), levels of C4 and C3 were chronically
low. In some patients, even if C3 levels rose to normal range, C4 levels
remained low. Patients with this profile are often characterized by low
copy-number of C4 genes. (B) The second profile had frequent and
parallel fluctuations of serum C3 and C4. Patients with this profile had
active disease, and low C3 and low C4 roughly correlated with disease
activity. In the third profile (C), C4 and C3 protein levels stayed in the
normal range most of the time, except at the time of diagnosis and during
a disease relapse. Patients with this profile had relatively inactive disease.
Patients with the second and third profiles have normal gene copynumber of total C4 but may have a heterozygous deficiency of C4A
[modified from Reference (12)].
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In parallel to the discovery of common CNV for C4A and C4B
genes that contribute to quantitative and qualitative phenotypic
diversities of innate immunity and associations with autoimmune
diseases, another far-reaching observation related to application
to cell-bound C4d occurred in the field of organ transplantation.
The deposition of C4d on the endothelium of capillaries for renal,
heart, and lung grafts is recognized to be a diagnostic biomarker or
“immunohistochemical imprint” of alloantibody-mediated complement activation that leads to graft rejection. In transplant recipients, preexisting or de novo donor specific alloantibodies binding to
graft cells may activate complement and cause graft injury. In acute
and chronic rejections of renal grafts, peritubular capillary (PTC)
deposition of C4d occurred in about 30% of biopsy specimens and
detection of diffuse PTC-C4d often associates with poor renal graft
outcome. Reviews of C4d-deposition on graft capillaries as a result
of humoral alloreactivity can be found in Ref. (35–37).

mouse model of peripheral tolerance resulted in high titers of
anti-nuclear antibodies (ANAs) and a severe lupus-like disease.
These two concepts of debris clearance and regulation of
self-tolerance are not exclusive and likely overlap, or together are
responsible for the development of SLE in humans deficient in
early components of the CP.
In the following sections, we will describe genetic complement
deficiency states associated with SLE for each component of the
early CP (C1q, C1r, C1s, C4, and C2).

Complement C1q Deficiency

Three different genes (C1qA, C1qB, C1qC) closely linked on the
short arm of chromosome 1 encode for the C1q protein, which is
composed of 18 polypeptide chains. Inter-chain disulfide bonds
are formed via the cysteine residue in the N-terminal region of
each chain. Following the N-terminal region is a collagen-like
region (CLR) of ~81 residues. One A chain and one B chain
form a heterodimer during biosynthesis, and two C chains form
a homodimer, both through disulfide linkages via conserved
cysteine residues. Two A–B heterodimers associate with one C–C
homodimer to form a hexameric structure, of the composition
ABC–CBA. Three of these hexamers, with a total of 18 polypeptide chains together, form the tulip-like structure of C1q with
a collagenous tail and six globular regions, each with globular
heads ghA, ghB, and ghC.
The CP of activation is initiated by the C1 complex, of which
C1q is the first subcomponent. When C1q in the C1 complex
binds to IgM or IgG present in an immune complex, a binding site
of C1r/C1s is exposed, allowing further activation of the complement pathway (47–49). C1q is an important opsonin to promote
phagocytosis of apoptotic cells or debris, which can be archived
directly without complement activation through binding at the
collagenous region of C1q to calreticulin (CRT) in apoptotic cell
blebs and to CD91 on phagocytes; or indirectly with activation
of the CP as C1q binds to CRP ligated to phosphorylcholine/
phosphatidylserine or to SAP ligated to fragmented chromatin
from apoptotic cells, generating processed products C4b, C3b,
iC3b, C3dg, and C3d that are ligands for CR3 and CR4 on myeloid
cells to initiate phagocytosis.
The number of reported cases of homozygous deficiency of
C1q has increased to 74 (3, 50–52). Among the reported C1qdeficient subjects, the median age of (any) disease onset was
6 years. The clinical presentations among C1q-deficient patients
varied considerably, but the two common observations were:
(a) SLE or lupus-like disease in 88% and (b) recurrent bacterial
infections in 41% (40, 52). Some patients (17%) died at a young
age secondary to septicemia. Among the C1q-deficient patients
with SLE or lupus-like disease, cutaneous disorders, especially
photosensitivity, were prominent with a frequency of 84%.
Glomerulonephritis and neurologic disease affected about 30 and
19% of patients, respectively. Oral ulceration occurred in 22% and
arthritis/arthralgia in 16%. Immunologically, most C1q-deficient
patients had normal serum levels of complement C4 and C3,
high frequency of ANAs (particularly anti-Ro/SSA) but a low
frequency of anti-dsDNA.
Several different causative mutations have been identified in
patients with complete C1q deficiency. A variety of mutations

HEREDITARY GENETIC DEFICIENCIES
OF EARLY COMPLEMENT COMPONENTS
IN SLE
Deficiencies or genetic polymorphisms of early complement
components are strongly associated with increased risk of
developing SLE or a lupus-like disease (Figure 3). Complement
deficiencies are hypothesized to be associated with increased
susceptibility of SLE for several reasons. Functionally, the role
of complement includes the identification, opsonization, and
proper disposal of apoptotic cells and immune complexes formed
regularly between antibodies and foreign or self-antigens (1, 38).
An inability to efficiently clear apoptotic cells could render them
a source of autoantigens and thereby drive autoantibody production. Impaired clearance of immune complexes and “self ” debris
provides a logical explanation for complement deficiency in the
induction of SLE (39). While there are multiple complement
pathways to assist the host with clearance of these types of materials that accumulate continuously in healthy subjects, the CP is
essential through at least C4, and to a lesser degree C2, to properly
handle and dispose of immune complexes and apoptotic debris.
Another hypothesis that attempts to explain the association of
complement deficiency with SLE suggests that the complement
system is involved in immune tolerance (44). In other words,
early components of the CP are engaged in the “cross-talk” to
the adaptive immune system to achieve tolerance against selfantigens, or in the discrimination of “self ” versus “non-self.” A
complement deficiency that results in a breach of self-tolerance
provides a reasonable explanation for association with SLE
(45, 46). Normally, complement receptor 1 (CR1/CD35) and
complement receptor 2 (CR2/CD21) on follicular dendritic cells
of peripheral lymphoid tissues (such as the spleen and lymph
nodes) bind to and deliver self-antigens coated with complement
fragments to the autoreactive B-cells, which are anergized or kept
away from germinal center reactions. Previously, it was demonstrated in mouse models that complement was necessary for the
elimination of self-reactive lymphocytes during the maturation
of the immune system (46). Specifically, Prodeus et al. showed
that deficiency of either CD21/CD35 or of C4 in a well-defined
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FIGURE 3 | SLE patients with a homozygous deficiency of early components for the classical pathway of complement activation. Severe cutaneous
lesions are common clinical presentations in SLE patients with a complete complement deficiency. (A) A homozygous C1q-deficient male child with cutaneous
infection (upper panel) and with discoid lupus erythematosus and scarring lesions on face when he was 22 years old (lower panel). (B) A male child with discoid
lupus at 16-month old with homozygous C1r-deficiency. This patient experienced generalized seizures, developed a scissoring gait with toe walking, spasticity and
weakness of the legs. At 18 years old, he was diagnosed with class IV lupus nephritis and progressed to end-stage renal disease. (C) A complete C4-deficient girl at
3 years old with butterfly rash and cheilitis (upper panel), and osteomyelitis of the femur at 10 years old (lower panel). This patient died at age 12 because of
pulmonary infection and cardiovascular failure. (D) A homozygous C2-deficient young woman with acute cutaneous lupus erythematosus. The upper panel shows
the butterfly rash, and the lower panel shows photosensitive lesions on sun-exposed areas [adopted from Ref. (40–43)].

tail-to-tail orientation with their 3′ ends separated by ~9 kb. The
DNA sequence for the genomic region harboring human C1s and
C1r coding sequences is still incomplete in the Reference Genome
(Annotation release 106, January 2015) and consists of gaps.
C1r and C1s are paralogous proteins that share 38% identity
and 55% similarity. Each mature protein is a proenzyme consisting of six distinct modules: two CUB domains separated by an
EGF domain with a binding site for Ca2+, followed by two complement controlling protein repeats CCP1 and CCP2, a linker
segment and then a chymotrypsin-like serine protease domain SP
at the carboxyl-terminus region. In circulation, C1r and C1s are
proenzymes that exist as a tetrameric structure, C1s–C1r–C1r–
C1s, which assembles in the presence of Ca2+ with C1q to form
the multi-molecular C1 complex. Upon activation of C1q (e.g.,
through binding of its globular heads to the Fc-regions of IgG or
IgM in an immune complex), the tetramer interacts with the hinge
region of C1q to form the activated C1 complex. Autoactivation
of the two C1r by proteolytic cleavages between Arg-463 and
Ile-464 is followed by activation of C1s by proteolysis between
Arg438 and Ile-439, which release the enzymatic activity of the
nascent C1 complex. The C1s in this C1 complex activates C4
and then C2 which together form the CP C3 convertase, C4b2a.

(including non-sense, frameshift indels, and splice site) result in
the absence of biosynthesis of one of the three C1q (A, B, or C)
chains. Other mechanisms have been identified by which C1q
protein is defective in secretion, structure, or function. In Table 1,
the molecular basis of the genetic mutations leading to complete
absence or complete functional deficiency of C1q protein for
which genetic information is reported, as well as the accompanying clinical manifestations.
Most of the causative mutations associated with homozygous
C1q genetic deficiency are the result of a consanguineous marriage.
The affected patients are likely close descendants of ancestors carrying the specific deleterious mutation. Surprisingly, screening
of large SLE cohorts from those countries with reported cases of
C1q deficiency to determine the prevalence of C1q deleterious
mutations have yielded negative results (59, 78), suggesting that
the mutations are “private” and rare but with very large effect size,
as documented in many complex diseases (79, 80).

Complement C1r and C1s Deficiency

The genes for human C1s and C1r are located on the short arm
of chromosome 12 (81). According to bioinformatics studies
and previous publications (82), C1r and C1s are configured in a
Frontiers in Immunology | www.frontiersin.org
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TABLE 1 | Complete deficiency of A, B, or C chain genes of C1q.
Location

Mutation

Molecular defect

Age of onset
(years), sex,
ethnicity

1

C1qA

M1R

2

C1qA

M1R

Start codon mutation; no
detectable protein
As above

3

C1qA

Q208X

Nonsense mutation

nk, M,
African-Americana
nk, M,
African-Americana
10, M, Turkish

4

C1qA

Q208X

As above

4, F, Turkishb

5
6
7

C1qA
C1qA
C1qA

Q208X
Q208X
Q208X

As above
As above
As above

6, F, Turkishb
nk, F, Turkish
3, F, Turkishc

8

C1qA

Q208X

As above

15, F, Turkishc

9

C1qA

Q208X

As above

4, M, Turkish

10

C1qA

Q208X

As above

1, M, Turkish

11

C1qA

Q208X

As above

1, M, Iraqi

12
13

C1qA
C1qA

W216X
W216X

Nonsense mutation
As above

0.5, F, Sudanesed
3, M, Sudanesed

14

C1qA

1-bp deletion;
Q64X

3, M, Caucasian

15

C1qB

16

C1qB

Point mutation
(RFLP analysis
only)
G42D

17
18

C1qB
C1qB

G42D
G42D

Frameshift
mutation → premature
stop codon
Premature stop codon;
functionally deficient
protein
Glycine mutation; LMW
C1q; complete functional
deficiency
As above
As above

19
20

C1qB
C1qB

G42D
G244R

21
22
23

C1qB
C1qB
C1qB

G244R
G244R
G63S

24

C1qB

6251A > C

25

C1qB

187G > T

26

C1qC

G34R

27

C1qC

G34R

As above
Glycine mutation; no
detectable protein
As above
As above
Missense mutation; C1q
unable to associate with
C1r and C1s
Splice site mutation; no
detectable protein
Splice site mutation;
complete functional
deficiency
Glycine mutation; LMW
C1q; complete functional
deficiency
As above

28

C1qC

G34R

As above

0.5, F, Arabian

29

C1qC

G34R

As above

21, F, Caucasian

4, M, Pakistani

16, F, Moroccane

23, M, Moroccane
3, M, Moroccane
nk, M, Moroccane
3, F, Inuitf
14, F, Inuitf
2, F, Inuitf
20, M, Arabian

2, M, Caucasian
4, F, Japanese

Clinical presentations

Reference

SLE

(53)

Lupus, premature death

(53)

History of ear and oral infections, recurrent skin
lesions, premature death at age 10 from septicemia
Malar rash, stomatitis, ANA, premature death at
age 6 from sepsis
Facial swelling, hematuria
Asymptomatic at age 22
SLE, glomerulonephritis, arthralgias,
photosensitivity, anti-Ro autoantibodies
Photosensitive rash, microscopic hematuria, IgA
nephropathy
SLE-like disease, meningitis, pneumonia,
meningococcal sepsis, ANA
Rash, recurrent upper respiratory tract infections,
low ANA
Erythematous rashes, otitis media,
glomerulonephritis, fatigue, photosensitivity, ANA
SLE, cutaneous lupus, bacterial meningitis, ANA
SLE, cutaneous lupus, bacterial meningitis,
bacterial keratitis, polyarthritis, ANA
Photosensitivity, malar rash

(54–56)
(56, 57)
(56, 57)
(58)
(59)
(59)
(60)
(61)
(52)
(52)
(52)
(52)

SLE-like disease, history of fever,
glomerulonephritis, discoid facial lesions, ANA,
premature death at age 8
SLE, arthralgia

(62, 63)

SCLE, ANA, anti-Sm autoantibodies
SLE, ANA, anti-ds DNA autoantibodies,
thrombocytopenia, growth retardation
Asymptomatic at age 42
DLE, photosensitive malar rash, ANA, recurrent skin
and mucosal lesions
SLE, ANA, arthritis
Lupus erythematosus, vasculitis, pneumonia, ANA
SLE, CNS involvement, recurrent infections;
premature death due to bacteria-induced septic
shock
Recurrent upper airway infections, history of fever
and seizures
DLE, history of fever, facial erythema, joint pain, oral
ulcerations

(64, 65)
(64, 65)

(64, 65)

(64, 65)
(66)
(66)
(66)
(67)

(68)
(69)

4, F, Indiang

DLE, photosensitivity, ANA

(70)

0.8, M, Indiang

Umbilical sepsis, erythematous rash, ANA, parotitis,
anti-Ro autoantibodies
SLE-like disease with CNS involvement,
recurrent bacterial infections, ANA, anti-dsDNA
autoantibodies, hyper-IgM syndrome
Adult-onset of SLE-like disease, history of fever,
oral ulcerations, bacterial meningitis, ANA, anti-Ro
autoantibodies

(70)
(71)

(72)

(Continued)
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TABLE 1 | Continued
Location

Mutation

Molecular defect

Age of onset
(years), sex,
ethnicity

30

C1qC

R69X

Nonsense mutation

9, F, Caucasian

31
32

C1qC
C1qC

R69X
G76R

10, M, Kosova
8, F, Turkish

33

C1qC

delC43 fs108X

As above
Glycine mutation; no
detectable protein
Frameshift premature
stop codon at 108

34
35

C1qC
C1qC

delC43 fs108X
1bp
deletion → 83X

As above
Frameshift mutation
premature stop codon
at 83

1, M, Yugoslavianh

3, M, Yugoslavianh
6, F, Pakistani

Clinical presentations

Reference

Severe SLE, with cutaneous and CNS involvement,
ANA, anti-Sm and anti-Ro autoantibodies,
cytomegalovirus retinitis, premature death at age 28
from CNS involvement
Malar and discoid rash, ANA, oral ulcerations
Recurrent meningitis, pneumonia

(70, 73)

SLE-like disease, photosensitivity, butterfly rash,
glomerulonephritis, ear infections, ANA, anti-Sm
and anti-Ro autoantibodies
SLE-like disease, cutaneous vasculitis, ANA
Erythematosus rash, recurrent urinary and
respiratory infections, ANA, anti-Sm autoantibodies

(70, 75)

(52)
(74)

(70, 75)
(76, 77)

Individuals marked with matching superscripts are from the same family.
nk, age of onset is not known; DLE, discoid lupus erythematosus; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus; LMW, low molecular
weights; ANA, antinuclear antibodies.

a–h

Deficiencies in subcomponents C1r and C1s were among
the earliest reports linking complement deficiency with human
glomerulonephritis or a lupus-like disease (83–85). A total of
20 cases of C1r and/or C1s deficiencies have been reported,
which include 12 cases of C1r deficiency from eight families
and eight cases of C1s deficiency from five families. Among
the C1r-deficient patients, there was a consistent reduction in
the serum protein levels of C1s to 30% of its normal level, but
highly elevated serum protein levels of C4, C2, and C1-inhibitor
(200–400% of their corresponding normal ranges). C3 was
also elevated by ~50%, but C1q levels were normal. A similar
phenomenon was observable among C1s-deficient patients;
C1s-deficient patients had greatly reduced serum levels of C1r,
markedly elevated levels of C4, C2, C1-inhibitor, and C3, and
normal levels of C1q.
Among the C1r/C1s deficient subjects, all but three had recurrent bacterial, viral, or fungal infections (85%), and many patients
died at young age because of a severe infection. Thirteen subjects
(65%) developed SLE or a lupus-like disease. The prevalence of
ANA among these patients was about 60%. Mortality at young age
from infections likely explains the slightly lower frequency of lupus
disease association compared to C1q deficiency. Most C1r/C1s deficient patients had severe cutaneous lesions (Figure 3). Eight patients
(40%) had renal disease due to lupus nephritis. Such presentations
underscore the inter-dependence of C1r and C1s in sustaining a
stable tetrameric structure that would otherwise be susceptible to a
high turnover rate. A deficiency of C1r or C1s prevents the formation of the C1 complex and diminishes the need for engagement of
C1-inhibitor and other regulators of complement activation. When
C1 is not functional, the CP is not activated, and consumption of
C4, C2, and C3 is greatly reduced, resulting in high levels of these
proteins in the circulation (41). This and other results strongly
indicate a chronic turnover of component proteins for the CP (86).
The molecular defects leading to C1r or C1s deficiency
have been determined in one case of C1r deficiency and seven
cases of C1s deficiency (Table 2). Relative to C1r deficiency,
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the defect was a homozygous C to T substitution in exon 10
resulting in the R380X non-sense mutation in the second CCP
domain, resulting in no detectable protein in the serum (41).
The proband developed SLE at 3 months of age and presented
with reduced levels of C1s (similar to other C1r-deficient
patients), but highly elevated protein levels of C4, C2, and C1
inhibitor.
For C1s-deficiency, several deleterious mutations have been
identified. A C→G mutation in exon 6 (Y204X) resulted in a
premature stop codon and abrogated any protein production
(87). This particular non-sense mutation was homozygous in
four siblings, and all showed no detectable C1s protein, but
only two developed SLE at the ages of 7 and 13 years. The other
two siblings, at ages 10 and 20, did not have clinical symptoms
of SLE. Significantly reduced levels of C1r and elevated serum
C4 were detected in all four siblings. In another case report, a
4-bp deletion (TTTG) in exon 10 that led to a frameshift and
a non-sense mutation in exon 12 (E597X) was detected in a
single patient (88, 89). This patient developed unique symptoms
including virus-associated hemophagocytic syndrome and died
after a long period of a comatose state. A mutation documented
in another patient from the same family was a heterozygous
G → T mutation in exon 12 leading to E597X and on the other
allele, a novel missense mutation G630Q (90). This patient displayed symptoms that were similar to the other, related patient,
including fever of unknown origin and short-term disturbances
of consciousness. A second C1s genetic variant is a non-sense
C → T mutation in exon 12 (R534X) (91). This patient had
undetectable serum C1s, normal C1r and C1q, and absence of
CH50 activity. The patient was 2 years of age and presented with
several autoimmune diseases, including a lupus-like syndrome,
Hashimoto’s thyroiditis, and autoimmune hepatitis. Each of
these clinical observations and the similarities in autoimmune
presentation with C1r/C1s deficiencies highlight the role of a
dysfunction in the CP of complement leading to systemic autoimmune disease.

8

February 2016 | Volume 7 | Article 36

Lintner et al.

Complement in Systemic Autoimmune Diseases

TABLE 2 | Molecular defects and clinical presentation of complete deficiency for C1s or C1r.
Location

Mutation

Molecular defect

Age of onset (years),
sex, ethnicity

1

C1s, Exon 6

Y204X

Nonsense mutation; no
detectable protein

7, F, Braziliana

2

C1s, Exon 6

Y204X

13, M, Braziliana

3

C1s, Exon 6

Y204X

4

C1s, Exon 6

Y204X

5

C1s, Exon 10,
Exon 12

4-bp
deletion + E597X

Nonsense mutation; no
detectable protein
Nonsense mutation; no
detectable protein
Nonsense mutation; no
detectable protein
Frameshift mutation leading
to non-sense mutation; no
detectable protein

6

C1s, Exon 12

G630Q + E597X

13, F, Japaneseb

7

C1s, Exon 12

R534X

Missense mutation; nonsense mutation; truncated
protein (functionally inactive)
detectable at extremely low
levels in serum
Nonsense mutation; no
detectable protein

8

C1r

R380X

Nonsense mutation; no
detectable protein

Clinical Presentations

Reference

(87)

nk, M, Braziliana

SLE, recurrent infections (pneumonia,
septic arthritis, sinusitis), ANA, anti-Sm
autoantibodies, arthritis, proteinuria,
deposition of IgG and C1q on the glomeruli
SLE, arthritis, ANA, anti-Sm autoantibodies,
photosensitivity
Asymptomatic at age 20

nk, M, Braziliana

Asymptomatic at age 10

(87)

4, M, Japaneseb

Virus-associated hemophagocytic syndrome;
history of fever; seizures with loss of
consciousness leading to premature death
at age 7
History of fever and pain, ANA, seizures, and
periods of unconsciousness

(88, 89)

Recurrent malar rash, mild fever, pain and
swelling in joints, lupus-like syndrome,
Hashimoto’s thyroiditis, autoimmune hepatitis
SLE, discoid lupus rash, diffuse proliferative
glomerulonephritis, transverse myelitis

(91)

2, F, Caucasian

0.3, M, African
American

(87)
(87)

(90)

(41)

a–b
Individuals marked with matching superscripts are from the same family.
nk, age of onset is not known; SLE, systemic lupus erythematosus.

Complement C4 Gene Copy-Number
Variations and C4A or C4B Isotype
Deficiency

by gel electrophoresis, but not from sera when many regulatory
proteins are present (15, 96).
The primary site for C4 biosynthesis is in the liver. However,
multiple tissues also synthesize C4, presumably for local consumption, particularly after stimulation by interferon-gamma
(100). A thioester bond is present but hidden in native C4. A
proteolytic cleavage by activated C1s removes a 74 amino acid
C4a peptide and leads to a remarkable change of conformation
in C4 (101). Consequently, the protected thioester bond becomes
exposed to the exterior. In activated C4B, one of the four isotypic
residues (Histidine-1125) serves as a catalyst and facilitates a
rapid nucleophilic attack, resulting in formation of a covalent
ester linkage between C4B and the target surface (102, 103). In
activated C4A, Histidine-1125 is not present, and such a catalytic
reaction does not occur. Instead, C4A reacts effectively with an
amino group on an immune complex or a protein molecule
to form a covalent amide bond. Such a difference in chemical
reactivity appears to diversify the functional roles of C4A and
C4B in the clearance of immune complexes and the propagation
of activation pathways, respectively.
A complete or homozygous genetic deficiency of both complement C4A and C4B has been reported in 28 individuals (42,
104–107). The subjects came from 19 families with different racial
backgrounds were characterized by 16 different HLA haplotypes.
The female to male ratio was 1:1. SLE or lupus-like disease was
diagnosed in 22 (78.6%) of the C4-deficient subjects, and four
others had renal disease including glomerulonephritis. Early
disease onset, severe photosensitive skin rash, the presence of

The complement C4 gene is located in the HLA class III region
on the short arm of chromosome 6, telomeric of the C2 gene (92).
Remarkably, there are extensive inter-individual gene CNVs for
complement C4. Two to eight copies of C4 genes can be present
in a diploid genome (93, 94) (Figure 4). Such common CNVs
are an uncommon phenomenon in mammalian genetics, as they
deviate from the conventional “one-to-one” concept for a gene
and a polypeptide/gene product. Here, one to four copies of
nearly identical genes co-exist on a single chromosome, thereby
creating a gene dosage effect for a quantitative phenotype.
Segmental duplications for C4 always include the RP (STK19)
gene upstream of C4, and the downstream genes CYP21 and
TNX (94). Each C4 gene either encodes for an acidic C4A or a
basic C4B protein, with only four amino acid changes (PCPVLD
1120–1125 for the C4A isotype and LSPVIH for the C4B
isotype), but this results in substantial differences in chemical
reactivity for peptide and carbohydrate antigens (28, 29, 31, 95).
C4A favors binding to amino groups (i.e., immune complexes)
while C4B favors binding to hydroxyl or carbohydrate-rich
groups. Approximately 40 protein variants for complement C4
have been documented (25). Technically, it is noteworthy to
mention that the differential binding to hydroxyl- or amidegroup containing substrates/immune complexes, or hemolytic
activities between activated C4A and C4B can be readily demonstrated using purified component proteins or proteins resolved
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FIGURE 4 | Gene size dichotomy and gene copy-number variation of complement C4. A human C4 gene consists of 41 exons coding for a precursor
protein of 1744 amino acids including a signal peptide of 19 amino acids. (A) There are two forms of C4 genes. The long gene is 20.6 kb, and the short gene is
14.2 kb. In a long C4 gene, an endogenous retrovirus HERV-K (C4), which is 6.4 kb in size, integrated into its ninth intron. Among healthy subjects of European
ancestry, 76% of C4 genes belong to the long form and 24% belong to the short form. (B) Among European subjects, one to four copies of C4 genes are present in
the central region of the major histocompatibility complex (MHC) located on chromosome 6p21.3. Thus, there is a continuous variation in copy number of C4 genes
from two to eight copies among different human subjects. (C) The duplication of a C4 gene occurs in a modular fashion, with a 0.9 kb fragment of RP (STK19)
upstream of complement C4, a full steroid cytochrome P450 21-hydroxylase (CYP21) and a 4.0 kb fragment of the tenascin (TNX) at the downstream region of C4
(known as a RCCX module). The duplication of CYP21 gene can be a pseudogene (CYP21A or CYP21A1P) or an intact functional gene (CYP21B or CYP21A2).
Each C4 gene in the RCCX module may either code for an acidic C4A or a basic C4B. Each C4 gene may be either long or short [adopted from Ref. (97–99)].
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autoantibodies against ribonuclear protein Ro/SSA, and high
titers of ANA were common clinical features of the subjects.
Many of the C4-deficient patients also had severe proliferative
glomerulonephritis. We have summarized the molecular basis of
complete C4 deficiency determined in 15 cases (Table 3).
While a complete deficiency of C4 is rare, an isotype deficiency
of either C4A or C4B is much more commonly observed and has
been implicated in several autoimmune diseases (13, 110–113). To
investigate the C4 genetic diversities in SLE, a study population
consisting of 216 female SLE patients, 17 male SLE patients, 362
first degree relatives, and 389 unrelated healthy female controls,
and 128 male controls was investigated rigorously (13). In the study
group of European Americans, total gene copy-number (GCN) of
C4 ranged from 2 to 6 copies, GCN of C4A ranged from 0 to 5
copies, and GCN of C4B ranged from 0 to 4 copies. In comparison
to healthy controls, SLE patients had significant reductions of GCN
of total C4 (Figure 5). Among the SLE patients, 9.3% had only two
copies of C4 genes, compared to 1.5% in healthy controls. The effect
size of SLE disease risk (or odds ratio) for subjects who had only
two copies of C4 genes was 6.51. Of the two C4 isotypes C4A and
C4B, there were no significant differences detected among GCN of
C4B between SLE and controls. However, significant decreases of
GCN of C4A were noted in SLE patients. Among SLE patients, 6.5%
had a homozygous deficiency (i.e., 0 copy) of C4A and 26.4% had a
heterozygous deficiency (i.e., 1 copy), compared to 1.3 and 18.2%,
respectively, in healthy controls. The odds ratio for SLE for a subject
with C4A homozygous deficiency of C4A was 5.27. In other words,
a total C4 GCN = 2 or a C4A GCN = 0 (C4A deficiency) are large
effect size genetic risk factors for human SLE. Moreover, family
based association tests revealed that monomodular RCCX haplotypes with a single short C4B gene and C4A deficiency were more
frequently transmitted to the SLE patients than normal heritance
pattern (p = 0.005). To date, no other common genetic variant has
been identified to be so strongly associated with SLE. Remarkably,
32.9% of SLE subjects carried the risk factor of low GCN of C4A. As
with most common genetic variants associated with autoimmune
disease, the risk factor is also present in the general population with
considerable frequency (19.5% in this study).
From another way of statistical analysis, C4 GCN variations
are continuous variations, and therefore, the mean of GCNs
for total C4, C4A, C4B long genes and short genes can each be
compared by Student’s t-test between patients and controls. The
mean GCN (±SD) for total C4 between female controls and
female patients were 3.81 ± 0.75 and 3.56 ± 0.77, respectively
(p = 0.0001). The mean C4A GCN (±SD) was 2.05 ± 0.79 in
controls and 1.81 ± 0.89 in SLE (p = 0.0005). The mean long C4
was 2.91 ± 1.03 in controls and 2.66 ± 1.14 in SLE (p = 0.005). In
other words, when compared with controls, SLE showed reductions of 0.25 copies of total C4, 0.24 copies of C4A, or 0.25 copies
of long C4. For C4B or short C4 genes, no significant differences
were observed between the European American SLE and racematched controls.
As the first original publication to document the highly
prevalent, multi-allelic gene CNVs of complement C4 in SLE,
this work (13) went through independent and rigorous data
generation and validation processes to confirm the CNV calls.
Those processes included (a) pulsed-field gel electrophoresis to
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resolve PmeI-digested genomic DNA fragments and Southern
blot analysis for long-range mapping to elucidate the physical
size of RCCX modules in haplotypes; (b) TaqI restriction digests
and genomic Southern blot analyses (restriction fragment length
polymorphisms) to resolve the relative dosages of RP1-C4L
(7.0 kb), RP1-C4S (6.4 kb), RP2-C4L (6.0 kb), RP2-C4S (5.4 kb),
plus relative dosages of CYP21B to CYP21A, and relative dosages
of TNXB to TNXA; (c) PshAI-PvuII digests of genomic DNA
and Southern blot analysis to segregate C4A and C4B and yield
their relative dosages; (d) immunofixation of EDTA-plasma for
polymorphic variants of C4A and C4B proteins resolved by high
voltage agarose gel electrophoresis, based on differences in electric
charges of C4 allotypes; and (e) corroboration of C4 genotypes
and phenotypes of study subjects from data of family members.
Subsequently, TaqMan-based quantitative PCR amplicons for
total C4, C4A, C4B long genes and short genes were developed
and applied for replication studies, particularly when quantities
of genomic DNA for patients and controls are limiting. In this
later case, internal data validation is achieved when GCNs of total
C4 = GCNs of C4A + C4B = GCNs of C4 long + C4 short. Such
qPCR strategy is sensitive and highly robust when the quality of
genomic DNA is excellent, which can be reflected by internal
data validation of the independent amplicons. Our experience
suggested that genomic DNA samples at low concentrations
(≤15 ng/μl) are relatively unstable in storage, particularly if they
had gone through rounds of freeze-thaws, and tend to yield
inconsistent data in analyses of multi-allelic CNVs. This makes
individual internal data validation crucial for data accuracy.
Association of lower GCN of total C4 and C4A-deficiency as
a risk factor of SLE have also been observed in three independent East-Asian studies (114–116). C4A deficiency in subjects of
European ancestry is primarily attributed to the presence of a single short C4B gene (mono-S) in the HLA that is predominantly
in linkage disequilibrium with HLA A*01, B*08, and DRB1*0301
that is dubbed ancestral haplotype 8.1 (AH8.1) (117). Intriguingly,
such AH8.1 haplotype is basically absent among East-Asian
subjects (Figure 6), supporting the evidence that C4A-deficiency
association with SLE is not due to linkage disequilibrium with
certain HLA haplotypes (e.g., DRB1*0301). Different mechanisms leading to C4A deficiency in East Asians include
(a) monomodular RCCX with a single long C4B gene, (b)
bimodular RCCX haplotypes encoding C4B1-C4B96 or
C4B1-C4B1 are prevalent in Asian SLE (116). Certainly other
genetic or environmental risk factors, combined with the
C4A deficiency, contributed to SLE development in genetically predisposed patients. Still, it is of interest to examine if
restoring C4A in such (C4A-deficient) patients would result
in positive therapeutic outcomes.
On a recent case/control study of British SLE (cases,
N = 501; controls, N = 719), total C4 GCNs were determined by
a paralog ratio test, which employed a set of primers (16-mer)
that hybridized to and PCR-amplified the duplicated regions
of complement C4 in the MHC plus a unique and non-variable
region in chromosome 19 as reference control (for two copies).
C4A and C4B were deduced from the ratios of C4A and C4B
that is determined by NlaIV restriction digest of a different
PCR product spanning the C4-isotypic site (158 bp for C4B
11
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TABLE 3 | Molecular defects and clinical presentations of complete deficiency of complement C4A and C4B.
Location

Mutation

Age of onset (years),
sex, race/ethnicity

1

Exon 20

Homozygous 1-bp
C-deletion, codon 830;
premature stop
Heterozygous; identical
2-bp insertion to
codon 1232 of all three
C4 genes
As above
2-bp insertion in codon
1232 of C4A; 1-bp
deletion in codon 541
of C4B

2, F, Swedish

2

Exon 29

3
4

Exon 29
Exon 29;
Exon 13

5
6

Exon 29;
Exon 13
Exon 13

As above

42, M, US-French
descentb
10, M, Austrian/Italian

7

Exon 13

As above

5, M, Austrian/Italianc

8

Exon 13

As above

2, F, Austrian/Italianc

9

Intron 28,
splice
donor

g8127a (GT → AT)
both C4B genes

17, M, Austrian/Italian

10 Intron 28,
splice
donor

g8127a (GT → AT)
both C4B genes

6, F, Austrian/Italiand

11 Intron 28,
splice
donor

As above

5, M, Austrian/Italiand

12 Intron 28,
splice
donor

As above

5, F, Austrian/Italiand

13 Exon 13

R559X

6, M, Moroccane

14 Exon 13

As above

17, M, Moroccane

15 Exon 36

4-bp (GACT) insertion
at codon 1555,
Y1556X; both C4A
and C4B

12, F, Algerian

GT-deletion in codon
516

30, F, Finnisha

nk, M, Finnisha
9, M, US-French
descentb

Clinical presentations

SLE-like disease, atypical rash, ANA,
rheumatoid factor, persistent exanthem,
glomerulonephritis
Malar rash, photosensitivity, polyarthritis,
leukopenia, ANA (1/320), anti-Sm (1/1280),
weakly positive rheumatoid factor

RCCX

HLA

L (C4A)

A30 B18 DR3

(107–109)

LS (C4A-C4B)/L
(C4A)

A2 B39 Cw7
DRB1*1501/
A2 B40 Cw3
DRB1*1501
As above
A2 B12 DR6

(105)

(105)
(106)

As above

(106)

L (C4A)

A24 Cw7 B38
DR13

(104)

L (C4A)

A24 Cw7 B38
DR13

(104)

As above

As above

(104)

SS (C4B-C4B)

A30 B18 DR7

(104)

SS (C4B-C4B)

A30 B18 DR7

(104)

As above

As above

(104)

As above

As above

(104)

L (C4A)

A2 B17
DRB1*07

(42)

L (C4A)

A2 B17
DRB1*07
A1 B17
DRB1*13

(42)

Photosensitivity
As above
SLE, arthralgia, malar rash; photosensitivity; LS (C4A-C4B)
ANA (1/10240), positive for anti-Sm,
anti-U1 ribonuclear protein, anticardiolipins; class III nephritis, neurological
disease, brain vasculitis; Sjogren’s
syndrome, recurrent infections, Raynaud’s
phenomenon; died at age 23
Discoid rash, polyarthralgias, oral ulcers
As above
History of fever, macrohematuria, mesangial
GN; infection, nephrotic syndrome;
membranous GN
Renal failure, mesangial GN; skin disease
with facial rash; a brother died at 3 with
cerebral vasculitis and sepsis
SLE, history of fever, skin rash and lesions,
oral ulcers, microscopic hematuria,
mesangial GN; skin transplant
Henoch-Schoenlein purpura,
macrohematuria, nephrotic syndrome,
mesangial GN; hemodialysis at 23; renal
graft at 24; hematuria and proteinuria
recurred at 26; mesangial GN; chronic
allograft nephropathy; hemodialysis at
28; second renal graft at 36. A younger
brother with complete C4 deficiency (details
unavailable)
SLE, hypertension, erythema of face, hands
and arms; microhematuria, proteinuria,
membranoproliferative GN; chronic renal
failure; hemodialysis at 26; renal graft at 31
SLE, skin lesions, microhematuria,
proteinuria, MPGN; hemodialysis at 16,
cadaveric renal transplant at 18; chronic
renal graft nephropathy at 23, hemodialysis
at 24; meningitis – Aspergillus fumigatus
Hematuria and proteinuria, MPGN; facial
maculopapular rash; biopsy-proven skin
vasculitis; mental disorder, severe cerebral
vasculitis
SLE, malar rash, photosensitivity, discoid
rash, ANA (1/1280), positive anti-Ro/SSA,
proteinuria and microscopic hematuria, GN
Recurrent infections, hematuria
Malar rash, ANA (1/1024); anti-Ro, antiSm; moderate renal disease, recurrent
lung infections, bacterial meningitis;
osteomyelitis; died at age 12 related to
cardiopulmonary complications

Reference

LS (C4A-C4B)

(42)

a–e
Individuals marked with matching superscripts are from the same family.
nk, age of onset is not known; GN, glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; SLE, systemic lupus erythematosus.
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FIGURE 5 | Comparisons of frequencies for total C4, C4A, and C4B gene copy-number groups in SLE (red) and controls (blue). SLE patients (N = 216)
of European ancestry showed significantly higher frequencies for lower copy-numbers of total C4 (GCN = 2 or 3) and C4A (GCN = 0 or 1) compared to healthy,
race-matched controls (N = 389). Mean GCN for Total C4 in SLE (3.56 ± 0.77) was significantly lower than in controls (3.84 ± 0.69; p = 5.3 × 10−6, t-test). Similarly,
mean GCN for C4A in SLE (1.81 ± 0.89) was significantly lower than in controls (2.06 ± 0.76; p = 2.0 × 10−4, t-test) [modified from Ref. (13)].

FIGURE 6 | Race-specific distribution patterns of RCCX modules in human populations. The size dichotomy of C4 genes and copy-number variation of
RCCX modules on an MHC haplotype together create a repertoire of length variants among different human subjects, which also exist with race-specific distribution
patterns. (A) The most prevalent haplotypes of RCCX in Whites and Asian-Indians are the bimodular long-long (LL) and bimodular long-short (LS) in Blacks and
East-Asians. (B) Notably, monomodular-short (mono-S or S) haplotypes with a single short C4B gene and C4A deficiency is relatively common in White and Black
subjects but almost absent in Asians [modified from Ref. (118)].

and 91 bp for C4A after NlaIV digest) and were resolved by
capillary electrophoresis (119). While extensive GCN variations
and associated polymorphisms were observable for complement
C4, the difference on the mean copy number of total C4 between
British SLE and controls was only marginal (3.79 ± 0.98 in SLE;
3.89 ± 0.98 in controls; p = 0.046). On the other hand, the mean
copy numbers of C4A (1.82 ± 0.93 in SLE, 2.08 ± 0.93 in controls;
p < 0.001) and C4B (1.96 ± 0.93 in SLE and 1.81 ± 0.72 in controls; p < 0.001) were both significantly reduced in SLE. However,
in multiple logistic regression models, deficiencies of C4A or
C4B both became insignificant in the presence of DRB1*03. This
led the investigators to conclude that “…partial complement
C4 deficiency states are not independent risk factors for SLE in
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UK….” It is notable that there were significant differences in the
architecture of GCN group distributions between the British
(119) and the US study populations (13).
Going through the previously mentioned Boteva study on
C4-CNV determination, we note two issues that probably led to
data misinterpretation. The first was a lack of an internal data
validation for GCN calls. The second was an additional procedure
to overcome the artifacts introduced by heteroduplex formation
between multiple alleles during PCR, which would be resistant to
restriction digest (NlaIV). Resistance to NlaIV digestions would
therefore skew relative dosage of C4A and C4B and lead to misinterpretation of C4 copy-number calls (97, 120). As to dissecting
the relative roles of C4-CNVs or C4A-deficiency and HLA-DRB1
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alleles in SLE, the issues on the lack of internal validation for the
reliability of C4-CNV calls cannot be ignored.
The unprecedented variations of GCNs with high frequencies
of homozygous or heterozygous deficiency of C4A or C4B, and
continuous variations in copy-numbers from one to four copies
of C4 genes on each copy of chromosome 6 (or haplotype) among
healthy subjects and SLE patients inevitably pose great challenges
both technically and conceptually: the former for accurate data
acquisition and the latter for accurate data interpretation. Without
deliberate design and rigorous and independent validation strategies, unfortunately, many studies were inherently tainted with
misinterpretations or partially correct or inappropriate conclusions. On determining the roles of common and multiallelic
CNVs in health and disease such as those for complement C4A
and C4B, immunoglobulin Fcγ receptors FCGR3A and FCBR3B,
and neutrophil alpha-defensins DEFA3 and DEFA1, it is critically
important to have meticulous experimental design and methods
to acquire accurate and consistent data. Realization of the DNA
sequence basis that causes a phenotype or functional diversity is
essential for specific experimental method. As mentioned above,
the heteroduplexes issue during the PCR process needs to be
considered and resolved. Moreover, genetic studies of a complex
disease usually require hundreds to thousands of genomic DNA
samples from cases and controls, which are generally obtained
from multiple sources. For determination of common and
continuous CNVs, the high quality of genomic DNA samples
is essential. Heterogeneous quality of DNA samples has a high
tendency to yield inconsistent data. Under those conditions,
independent replication and rigorous internal validation methods of samples from every subject becomes a necessity.

The second form of Type 1 deficiency is present in HLA A3, B35,
DR4, BF-F, C2Q0, C4A3, and C4A2 (125). The cause is a 2-bp
deletion in exon 2 of C2 gene that leads to a non-sense mutation.
About 10% of C2 deficiency is secondary to the Type II deficiency in which the C2 protein is synthesized but not secreted.
The molecular defects identified as missense mutations are
C111Y, S189F, and G444R (126, 127). It is not clear how these
mutations block the secretion of C2 protein.
Unlike a deficiency of proteins for the C1 complex or C4
described earlier, the penetrance of C2 deficiency on SLE is about
10%. Similar to other risk factors for SLE, there is a female predominance for patients with C2 deficiency. C2-deficient SLE patients
tend to have early childhood onset but a milder disease process
with prominent photosensitive dermatologic manifestations,
speckled ANAs (the autoantibody specificity is common for the
Ro/SSA antigen), and a family history of SLE. Anti-DNA antibody
tests are usually negative, and severe kidney disease is rare.

ACQUIRED DEFICIENCIES AND
AUTOANTIBODIES TO COMPLEMENT
COMPONENTS
Autoantibodies have been reported that bind with high affinity
to complement proteins, particularly in SLE patients (128). Most
of these antibodies are not directed against native proteins, but
instead directed against neoepitopes. Such epitopes becomes
exposed in active or inactivated proteins or upon multi-molecular
complex assembly in the activation process or following proteolytic cleavage. The binding of these autoantibodies to complement proteins could lead to a state of an acquired deficiency and
contribute to disease pathogenesis similar to the way genetic
deficiencies do so. We will describe a series of autoantibodies that
have been detected in systemic autoimmune disease against early
components and regulators of the CP.

Complement C2 Deficiency

The complement C2 gene is located in the HLA class III region
on the short arm of chromosome 6. Serum C2 is a precursor
protein that is cleaved by activated C1 into two fragments: C2b
and C2a. C2a is a serine protease and forms the C3 convertase
along with C4b (denoted C4b2a) (38, 121). C2 also functions as
a critical component in the lectin pathway. MBL or ficolins in
complex with MASP-1 bind to relevant carbohydrate molecules
and activate MASP-2, which then cleaves C2 and C4, forming a
C3 convertase identical to that formed in the CP (122). Overall,
C2 functions as a key component in the classical and lectin pathway, thereby providing defense against microbial infection and
assisting in removal of immune complexes.
Among individuals of European descent, C2 deficiency
occurs with an estimated prevalence of 1/20,000, which probably
accounts for <1% of SLE patients. There are two types of C2 deficiency (123, 124). Type 1 C2 deficiency is caused by non-sense
mutations leading to the absence of protein biosynthesis. The
predominant form of such type 1 deficiency was a 28-bp deletion
that removed 9 bp from the 3′ end of exon 6 and 19 bp from the
5′ end of intron 6 in the C2 gene, leading to a skipping of exon 6
in the C2 mRNA and generation of premature stop codon (123).
Such 28-bp deletion is present in the HLA haplotype with A10
(A25) and B18 in the class I region, BF-S, C2Q0, C4A4, and C4B2
in the class III region, and DRB1*15 (DR2) in the class II region.
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Anti-C1 Autoantibodies

Approximately 30% of SLE patients synthesize autoantibodies
against C1q. Their presence correlates with anti-dsDNA, nephritis, and low C4 and C3 in about 75% of such patients (129–131). A
relevant question is whether the anti-C1q amplify the complement
activation by immune complexes. The development of anti-C1q
antibodies may arise in response to activation of the CP. Following
CP activation, C1q remains attached to immune complexes and
therefore is located at the site of inflammation. Proteases at the
inflammatory site may degrade IgG and C1q (autoantigen), generating multiple proteolytic fragments of IgG and C1q. This may
be an explanation for C1q antibodies and anti-IgG and anti-IgM
(rheumatoid factors) that develop in SLE patients.
A large study was recently reported in which one objective
was to assess the specificity of anti-C1q antibodies and their associations with SLE manifestations and diagnostic tests (132). The
authors confirmed the association of anti-C1q antibodies, low
complement (C4 and C3), and anti-dsDNA antibodies. Further,
this combination had the highest serological association with
renal disease. Anti-C1q antibodies were detected in 28% of all
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a general relief in such diseases seems illogical. Processing of
immune complexes is facilitated by deposition of complement
fragments, the ensuing binding of complement-decorated
immune complexes to CR1 on erythrocytes, and transfer to resident monocytes or macrophages for destruction and/or antigen
presentation. For that reason, blocking any step up to and including C3 could inhibit immune complex processing and possibly
exacerbate disease in autoimmune patients. Moreover, inhibiting
the complement system would further enhance susceptibility to
infections, on top of the increased frequency of infections already
observed in patients under immunosuppressive therapy.
On the other hand, complement activation is quite evident
and partly responsible for tissue damage seen in autoimmune
patients with established disease. In lupus, key mediators of
tissue damage include C4b/C3b, C5a/C3a, and the MAC, all of
which modulate membrane integrity or trigger inflammation
in a setting where autoantibodies are already present in large
amounts. Therapeutic goals should be aimed at inhibiting this
cellular injury and preventing production of the proinflammatory peptide fragments. In atypical hemolytic uremic syndrome
(aHUS), endothelial damage is mediated by over-activation of
the AP. Inhibition of C5 cleavage has proven to be an effective
therapy (142). Anti-C5 therapy has been effective in treatment
of antigen-induced arthritis or experimental autoimmune uveoretinitis in animal models (143, 144). Other studies in animal
models of arthritis that showed success in reducing inflammation
and preventing disease progression include treatment with CR1
(145), antagonists of C3a receptor (146), and the complement
regulator CD59 (147). Soluble CR1 prevented dysregulation of
C3 convertase in sera from dense deposit disease patients (148).
The same study reported that short-term use of soluble CR1
in a pediatric patient with end-stage renal failure normalized
the activity of the terminal complement pathway. Inhibition of
complement activation specifically in SLE with renal diseases
deserves to be assessed.
Another treatment approach is to replenish complement
proteins in patients with a complete complement deficiency. As
discussed earlier, complete genetic deficiencies of complement
are quite rare, but isotype deficiency and functional or acquired
deficiencies are quite common. An obvious approach seems to be
supplement or replacement of the missing component, systematically or locally. Currently, however, purified or recombinant complement proteins are not available for treatment purposes. One
report indicated successful treatment of a C2-deficient patient
with SLE using whole plasma preparations (149). Moreover, in
patients with established disease and low C4 or C3, an increase
in C4 and C3 is associated with a favorable response to treatment.
Fresh frozen plasma is able to restore C1q activity in C1qdeficient patients temporarily, but such activity drops off rapidly
within 2 weeks. Thus, weekly infusions of plasma become
necessary, which is burdensome, and confers its own risk of
infections and thrombotic complications (69). Unlike most other
component proteins of complement in blood, the primary site of
biosynthesis for C1q is not in the liver, but rather in myeloid cells
including macrophages, monocytes, and dendritic cells, which
originate in the bone marrow. The effect of restoring the C1q
protein to reconstitute complement function has been tested in

SLE patients, but were observed more frequently in patients with
renal disease in ~68%. Anti-C1q autoantibodies were observed in
5–10% of patients with related systemic rheumatic diseases. It was
suggested that the presence of anti-C1q antibodies contributes to
a nephritis flare (130).
The presence of autoantibodies against other components of
the C1 complex is less well established. A report of 15 SLE patients
demonstrated that seven of them had autoantibodies to C1s (133).
The binding of these antibodies to C1s was shown to enhance its
enzymatic activity for C4, providing possible additional explanation for low serum C4.

Anti-C1 Inhibitor Autoantibodies

An IgG autoantibody that inactivates C1-inhibitor (anti-C1-Inh)
was initially described in a patient with the acquired angioedema
(AAE) syndrome that mimics hereditary angioedema (134).
Anti-C1-Inh autoantibodies have also been described in SLE,
especially those exhibiting symptoms of angioedema (135, 136).
Anti-C1-Inh antibodies bind and inactivate C1-Inh so that it is
no longer available to participate in the regulation of C1. As a
result, the CP is excessively activated, leading to development
of angioedema as well as possibly more severe renal diseases. A
more recent study of 202 SLE patients and 134 healthy controls
detected anti-C1-Inh autoantibodies in 17% of SLE patients and
4% of controls (137). In SLE patients, the anti-C1-Inh levels correlated with the duration and activity of SLE but did not correlate
with SLE laboratory parameters, including serum levels of C3 and
C4. Conversely, 1–2% of hereditary angioedema patients develop
SLE, probably related to the chronically very low C4 and C2.

C3 and C4 Nephritic Factors

C3 and C4 nephritic factors are IgG autoantibodies that bind to
and stabilize the AP C3 convertase and the CP C3 convertase,
respectively. By binding the C3 convertases, C3 and C4 nephritic
factors prolong the half-life by preventing the regulation of C3
convertases. This results in uncontrolled complement activation
and increased consumption and depletion of serum C3. C3 and
C4 nephritic factors are associated with membranoproliferative
glomerulonephritis, acquired partial lipodystrophy, and postinfectious acute glomerulonephritis (138–140). Both of these
autoantibodies have been detected in SLE patients, and suggested
to be associated with renal disease, but their prevalence and role
in pathogenesis of systemic autoimmune disease is not well
documented (139–141).

THERAPEUTIC POTENTIALS OF
COMPLEMENT ABNORMALITIES IN
AUTOIMMUNE DISEASE
Because the complement system is increasingly found to be associated with autoimmune diseases, it is an attractive therapeutic
target. However, as discussed earlier, complement deficiencies are
overwhelmingly associated with increased susceptibility to autoimmune disease, most notably SLE. Therefore, at first glance, the
idea that treatment with complement inhibitors would provide

Frontiers in Immunology | www.frontiersin.org

15

February 2016 | Volume 7 | Article 36

Lintner et al.

Complement in Systemic Autoimmune Diseases

mouse models. Bone marrow transplantation (BMT) of hematopoietic stem cells from wild-type animals has been shown to be
effective in treating C1q deficient animals (150, 151).
Recently, BMT for hematopoietic stem cell therapy (HSCT)
has been performed in a single case of a Pakistani C1q-deficient
patient (152). In this particular case, involving a consanguineous
family, the father and five of his six sons had C1q-deficiency. The
father died of chronic glomerulonephritis at age 38, and one of his
sons died at age 17 months from Streptococcus pneumonia meningitis. Another son was incapacitated by a CNS vasculopathy at
17 years of age. The index patient is the third son who survived
S. pneumonia-induced meningitis at age 3 but developed an acute
CNS vasculopathy at age 10. At age 16, his disease was brought
under control through treatment with intravenous cyclophosphamide (pulse therapy) and B-cell depletion with rituximab.
However, he had a persistent lupus rash and increased levels of
anti-Ro (SSA-60) in addition to anticardiolipin antibodies. In view
of his poor prognosis, HSCT was performed using bone marrow
from his HLA-matched healthy brother, with graft-versus-host
disease prophylaxis. Restoration of hematopoiesis, myelopoiesis,
platelet production, and complement function with normal levels
of C1q and CH50 were observed 2–4 weeks after transplantation.
Such a result gives hope to SLE-patients with a C1q deficiency and
a severe clinical course, although further studies are desirable.

of complement activation C5b–C9 MAC were detected in DM
muscle and skin biopsies. A single case of an individual with a
complete C2 genetic deficiency was reported to have DM (165).
The observation of complement components and complement
fragments indicates the possible involvement of complement
pathways in tissue damage. Previous studies revealed that HLA
class II gene DRB1 allele *0301 (also known as DR3) is the major
immunogenetic risk factor for juvenile DM (JDM) (166–170).
However, also present in the HLA region is the locus for complement C4. Specifically, DR3 in European subjects is in strong
linkage disequilibrium with a particular C4 haplotype: a single
C4B gene but the absence of a C4A gene (118, 171). A recent study
found that C4A deficiency was independent of DR3 in association with JDM in a study of 95 patients and 500 race-matched
controls of European ancestry (113). In addition, the authors
demonstrated through multiple logistic regression analyses that
the concurrence of C4A deficiency and DR3 together contributed
toward the highest risk of JDM with an odds ratio of 3.2.

Rheumatoid Arthritis

Several autoantibodies that play a major role in the autoimmune
attack of synovia have been identified in rheumatoid arthritis
(RA). There are three major types of RA-associated autoantibodies (i) anti-cyclic citrullinated peptide/protein autoantibodies
(anti-CCP), (ii) autoantibodies against the Fc-fragments of
IgG (rheumatoid factor, RF), and (iii) anti-type II collagen or
glucose-6-phosphoisomerase autoantibodies (anti-G6PI). All of
these autoantibodies bind their respective self-antigen, leading
to increased levels of ICs and activation of the CP observed in
RA patients (172–174). CP activation in RA patients has also
been reported to be mediated by C-reactive protein (CRP) or
fibromodulin (175, 176). Complexes formed between CRP and
activated complement components were increased in the majority of RA patients and were further increased in patients with
active disease versus patients with inactive disease. Agents/components that mediate and trigger inflammation in RA are likely
derived from cartilage since disease activity subsides after joint
replacement. Sjoberg et al. showed that the cartilage component
fibromodulin can activate complement specifically by binding
C1q, thereby activating the C1 complex and the remainder of
the complement cascade (176). The evidence of complement
activation in synovial fluid and the identification of several complement-triggering agents in RA support complement-mediated
disease pathogenesis.
Depressed levels of complement proteins and elevated levels
of complement cleavage products and late components MAC
C5b–C9 were noted in tissue specific to RA pathogenesis, such as
synovial fluid (177–180). Furthermore, the subsequent generation of anaphylatoxins C3a and C5a in synovial fluid creates an
inflammatory state that attracts and activates neutrophils and
other myeloid cells to the site of complement activation in the
inflamed joints. The harmful effects of complement activation in
RA are remarkable and evident. A recent study of C4 genetics in
RA patients revealed that a deficiency of C4B genes was significantly more frequent in RA patients compared to non-RA patients
or healthy controls (110). In other words, 40% of RA patients had
a C4B deficiency compared to only 21.6% of controls, resulting

EARLY COMPLEMENT COMPONENTS IN
OTHER AUTOIMMUNE DISEASES
Complement activation products and genetic polymorphisms
have been observed and shown to contribute to inflammation
and tissue damage of autoimmune diseases besides SLE. We
will briefly summarize findings of complement activation and
involvement in a few other autoimmune diseases.

Antiphospholipid Syndrome

Anti-phospholipid syndrome (APS) is characterized by arterial or venous thrombosis and recurrent pregnancy loss. The
complement profile in general parallels that observed in SLE
with CP activation being predominantly involved (153–156).
Hypocomplementemia has been associated with fetal loss, preterm delivery, and low-birth weight (157). Serum complement
levels were significantly lower in patients with primary APS
compared to patients with APS associated with a connective
tissue disease (155). The patients with primary APS also had
higher levels of complement activation fragments C3a and C4a
demonstrating that the hypocomplementemia is, as expected, due
to complement consumption (154, 155).

Dermatomyositis

Of the inflammatory myopathies, dermatomyositis (DM) is the
one most reported to possibly be associated with a complementmediated pathogenesis (158). Complement-mediated destruction of perivascular endothelium and perifascicular ischemia of
muscle fibers in biopsies from DM patients have been demonstrated by multiple investigators (159–164). Circulating immune
complexes, IgG and IgM, complement C3, and late components
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in an odds ratio of 2.99 for RA subjects. Replication cohorts of
RA patients are needed to validate and strengthen the possible
association of C4B deficiency with RA, which could be secondary
to the prevalence of HLA-DR4.

(SNPs) in those complement genes that may modulate functional
protein activities or gene expression levels, the presence of other
complement autoantibodies or nephritic factors, dysfunctional
regulatory proteins, or toxic side effects of drugs that may also
contribute to inappropriate complement activation.
Genetic insufficiency and acquired deficiency of complement have medium to large effect size on disease susceptibility
in European SLE. The frequency and effect size of specific
genetic variants for a complex disease tend to be race specific.
Considering the high prevalence of renal disease in African,
Asian, and Hispanic SLE patients, it is of interest to further extend
investigations on the roles of complement risk factors in these
racial/ethnic groups.
Fluctuations in either hemolytic complement activity or levels
of serum C3 and C4 in SLE patients were noticed over half of a
century ago. More recently, high levels of processed C4d activation
product attached to multiple cell types of hematopoietic origin
are present in most SLE patients. Comprehensive data on genetic
and acquired risk factors, plus cross-sectional and longitudinal
profiling of autoantibodies and serum levels of native and activated complement proteins, and cell-bound levels of processed
activation products hold promise as more sensitive biomarkers
for SLE. Additionally, similar investigations should be extended to
other autoimmune or inflammatory diseases including Sjögren’s
syndrome, DM, RA, and antiphospholipid syndrome.

Sjögren’s Syndrome

As with many autoimmune diseases, there are a number of autoantibodies that have been reported in primary Sjogren’s syndrome
(SS). Therefore, complement activation via the CP may be involved
in the development and/or pathogenesis of primary SS. A frequent
clinical observation in primary SS is hypocomplementemia, particularly low serum levels of C3 and C4. Some studies reported
that in the most severe cases of primary SS, the complement
inhibitor C4b-binding protein was decreased in parallel with C3
and C4 levels, suggesting that dysregulation of complement may
mediate disease pathogenesis (181). It is generally hypothesized
that low C3 and C4 levels are a result of consumption by CP
activation mediated by ICs in primary SS patients. Recent studies
have showed that lymphoproliferative disease, mortality rates, and
other severe disease manifestations were significantly higher in
patients with low levels of C3 or C4 (182–184). Therefore, complement levels may be more a marker or predictor of disease activity
in established SS patients.

CONCLUSION
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